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SUMMARY 
Multiple Myeloma (MM) and other plasma cell malignancies initially present as an asymptomatic precursor 
state, known as monoclonal gammopathy of undetermlned signiflcance (MG US). When confronted to a mono-
clonal proteln in blood or urine tests, physicians should first exclude the presence of a treatment-requiring MM. 
They should be aware that there are two benign precursor states, that do not require anti-myeloma trealmen!. 
Both MGUS and Smoldering Multiple Myeloma (SMM) need an initial visit by a haematologist, with further 
follow-up tailored to the individual patient and disease characteristics. In the current article we describe both 
entitles, discuss their monitoring and resume the latest publications in their field. 
INTRODUCTION 
In 2014, the International Myeloma Working Group (lMWG) 
updated the diagnostic criteria for Monoclonal Gammopathy 
ofUndetermined Significance (MGUS), Smoldering Multiple 
Myeloma (SMM) and multiple myeloma (MM)' The dis-
tinction between the different disease stages is based on 
biological parameters and tbe presence of clinical symptoms 
or early signs of emerging myeloma disease (Table 1). MGUS 
is defined by a serum M-protein 1evel of <3 gldL, a bone 
marrow plasma ceil (EMPC) infiltration of <10%, and the 
absence of clinical complications. SMM is defined by serum 
M-protein (lgG or IgA) levcls of ,,3 gldL and/or clonai BMPCs 
of 10%-60% in the absence of a myeloma defining event 
(MDE) or amyloidosis.' The updated IMWG diagnostic cri-
teria for MM include the presence of M-protein in blood or 
urine, a BMPC infiltration of > 10%, or biopsy-proven bony 
or extrameduUary plasmacytoma as weU as a MDE. A MDE 
is defined by CRAB criteria fhypercalcemia, radiological 
bone lesions. anaemia, and renal faiture) or one or more of 
the foUowing biomarkers of malignancy: a clonai BMPC 
percentage of >60%, involved/uninvolved serum free light 
chain (sFLC) ratio of >100 or >1, and focallesions (FLs) 
detected by magnetic resonance imaging (MRD. 
MONOCLONAL GAMMOPATHY OF 
UNDETERMINED SIGNIFICANCE 
The incidence of MGUS is estimated at 3.4% in the general 
population over 50 years of age. This incidence increases 
with age from only 1. 7% in patients aged 50-59 years to 
6.6% beyond 80 years.' Several hereditary, genetic as weU 
as environmental factors play a role in the development of 
MGUS, including age, race, gender, familial history and obe-
siey. A recent French study demonstrated that the M-protein 
isolated from MGUS and MM patients, reacted in 57 (23.4%) 
of 244 patients studied with Iysates or proteins from infectious 
pathogens. Of these, EBV nuelear antigen-I (EBNA-l) was 
the most frequent target.' These results indicate that antigen-
driven stimulation of plasma cells could be an early patho-
genic mechanism that initiates monoclonal gammopathies. 
RISK OF PROGRESSION OF MGUS 
The average risk of evolution from MGUS to MM, amyloidosis 
or other lymphoproliferative disease is 1% per year, depen-
ding on the nature of the protein implicated (lgG or non-IgG), 
the monoclonal protein leve! (> 15g!l) and theFLC ratio 
(abnormal Ot nor). 5.' Using these three items, the Maya Clinic 
developed a simple score that aUows to stratify patients 
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TABLE 1 ~ ii1t~.<lIff8mr,I:af cfillQl1C$S b:!lWeenMGU$. SmoIdeMg ~'6 a<l(l Muilicie my:;1om8. 
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Abbreviations. MGUS: monoclonal gammopathy of undetennined significance, SMM: smolderlng multiple myeloma, 
MM: multiple myeloma BM: bone marrow. PC: plasma cel/s, FLC: free light chain, MRI: magnetic resonance imaging 
(adapted from 20) 
according to their r" k status: eg 5% of the patients that do 
not show any risk factors progress at 20 years. This percen-
[age increases to 58% if three factors are present.6 Of note, if 
the FLC ratio is very abnormal « 0.125 or > 8), the risk of 
progression is even higher, reaching 60.5% at 20 years.' 
Another significam risk factor of progression is a decreased 
serum level of both uninvoh-ed immunoglobulins (Hazard 
Ratio of 2) while a decrease in just one of them does not 
impact this risk.' Recently, two different teams showed that 
also the presence of translocation (4;14) and deletion 17p 
in the bane marrow clonaI plasma ceUs is associated with 
a higher risk of progression. 6,9 As such, when feasible, cyto-
genetics may allow the identification of a high-risk patier" 
group for whom a c10ser follow up might be beneficial. 
MONITORING OF MGUS PATIENTS 
While MGUS is relatively frequent, in the absence of symp-
toms the work-up rarely leads to a the diagnosis of an O\'ert 
disease. Moreover, ir is nO[ certain chat close follow-up, and 
an early diagnosis of MM, leads to a better prognosis, since 
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more than one third of the MGUS cases evolve to SMM 
and do not require any treatmemYi Furthennore, the \'ast 
majority of the MGUS patients will die from other diseases, 
As such , after the identification of the risk group and ex-
clusion of any evolution after three months, one could refer 
the patient ta his genera! practitioner for a follow-up every 
2 0:- 3 ye~!:: cr z.:lrtu&ll:\- i:: G.se cf Q!1e. Qi:" more risk fa~ tor5 . 
Moreoyer, if life expectancy is less than 5 years and/or the 
patient is older than 85 years, the follow-up can be omitted." 
If a progression is suspected, of course, the patient should 
be referred ta the haematologist for [urther investigations. 
Ta identify progression to myeloma or Iymphoma, biological 
and radiological tests are generally required to identify a 
disease progression. However a careful clinicat examinarion 
is needed to exc\ude complication of the monoclonal protein 
itself. Once the work-up has established the absence of 
these pathologies and the early follow-up did not show a 
rapid evolution of the paraprotein, the patient can be refer-
red ta his general practitioner ta assure the right follow-up 
(Figure 1). 
• 
• ~ TIP -
Follow-up by 
F'!HolTIi/ doctor 
Annual follow-up w.th 
blood an.d u.rine lests 
Treal accordingly 
FIGURE 1. Aigorithm for fo"ow·up of patients wlth monoclonal gammopathy of undeterrnined significance (MGUS). 
MONOCLONAL GAMMOPATHY OF CLiNICAL 
SIGNIFICANCE: A NOVEL CONCEPT 
Signs or symprams of a peripheral neuropathy must be inves-
tigated ra exclude paraneoplastie syndrome, in particular if 
IgM is the paraprotein implicated since the prevalence of 
symptoms can reach 31% versus only 6% in case of IgG sub-
type." Fifty percent of them are due ta ami-MAG (myelin-
associated glycoprotein) activity of the M componem and 
anotber 35% is related to anti-ganglioside aetivity. Amyloi-
dosis or POEMS syndrome (Polyneuropathy, Organomegaly, 
Endocrinopathy, Monoclonal protein and Skin change) must 
also be evoeated, especiaIly in case of lambda secretionlZ 
In case of a creatinine increase, myeloma or progression to 
myeloma must he excluded, but other, sometimes discrete 
but always severe troubles can emerge. This includes nephro-
tic syndrome in amyloidosis or in other light or heavy chain 
depasits (RandaIl type). Fanconi disease, caused by light 
chain deposits in the renal tubules, must a150 be recognised 
in case of Ionie and metabolic abnormalictes. Other para-
neo-plastic immune glomerulonephritis can aIso be obser-
ved. AIl these emities are known as MGRS (Monoclonal 
Gammopathy of Renal Sigrtificanee) as the abnormalities 
can he proved ta be related to the monoclonal pattern. A 
treatment could he envisaged. 50, in from of an unexplained 
renal impairment, lurther investigations must be perfromed 
and a kidney biopsy deserves serious discussionIJ 
Sorne dermatologie entities are also described. The Schnit-
zler syndrome which manifests with fever, unicarial rash 
and arthropathy (sometimes wlth organomegaly) is eaused 
by a monoclonal IgM paraprotein, especially kappa. Other 
skin diseases can be encoumered, such as necrobiotic xan-
thogranuloma or other skin changes, in particular in the 
POEMS syndrome. 
FinaIly, sorne haemorrhagic status can be observed in case 
of paraneoplastic deficiency of von Willebrand factor or fac-
tor X in amyloidosis. 
SMOLDERING MULTIPLE MYELOMA 
In contrast ra MGUS, SMM has a higher risk of progression 
ra symptomatic MM. However, bath diseases are considered 
as precursor disease stages and, by definition, both disor-
ders are asympramatic. The 2014 IMWG criteria, changed 
the group of ultra-high risk SMM (which was associated 
with an 80% risk of progression to MM) into the group 
treatment-requiring MM' This change aIlows physicians ta 
initiate an early therapeutic stTategy, that could avoid serious 
complications .nd where the potenti.1 benefit justifies the 
risks of taxicity. 
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TABLE 2, Pl1lgrxoSlc f~s cl f.gH:s!< SMM 
(Ptl'11a! flS1) 
1 Serum M-protein ;,30g/L 
l, ~9A~MM_ 1 
, - --1 
- Progressive increase in M-protein levai (evoMng type 1 
of SMM; increase in serum M-protein by ;,25% on 
2 successive evaluations within a 6-month period) 
- Immunoparesis with reduetion of 2 uninvolved immuno-
globulin isotypes 
Ab~orma! PC immunopher.otype 
r.::2:95~é cf 8MPCs are clona!) 
t(4:14) O( del(1 7PJ or 1q gain 
Inereased cireulating PCs 
M RI with diffuse abnormalities or 1 focal lesion 
DEi \'vit.~ nypermetabo!ic focal (esicns, but vv'ltnoul 
underlying cone Iylie iasions 
RISK OF PROGRESSION OF SMM 
The risk of progression of SMM was originally established by 
Kyle et al. based on a cohoIt of 236 patients with smoldering 
mycloma disease, defined by the old IMWG criteria." The 
esrimaœd risk of progression ta MM or amyloidosis was 
10% per year for the fiISt 5 yeaIS, then the progression rates 
decreased progressively, but after 20 years 72% of the patients 
progressed. The recent IMWG criteria consider ultra-high 
risk SMM as treatment-requiring MM. As such, this group of 
patients is no longer considered as SMM patients, which 
probably affects the initial progression risks that were des-
cribed by Kyle et al. Prospective studies are needed tO reassess 
this risk when the 2014 IMWG criteria are applied. 
ln the past decades, other prognostic factors that identified 
patients with a high risk of progression have been described. 
These risk factors are summarized in Table 2. PatientS th8.t 
do not present any of these risk factors can be considered as 
low-risk patien:s, -.vith ar: estimated risk of progression of 
5 to 10% per year. Sorne of these factors are based on routine 
tests, while others require complememary examinations. 
Routinely performed radiologieal and laboratory testS (im-
munoglobulin isotype, serum M-protein levels, sFLC levels, 
immunoglobulin quantification) can help to estimate this 
progression tisk in daUy practice. The use of cytogenetic 
evaluation is justified for young patients, but there is insuffi-
cient data to justify the systematic reahzation of a PET-CT 
for ev",y patient with SMM. 
VOLUIVl E9DBCE ,BER2018 
Researchers at the Mayo Clinic :-e-examined their cohort of 
patients with SMM who met the 2014- jMWG criteria to 
define their natural history and idemified sC\'eral risk factors 
for progression." They finally proposed a simple scoring 
syscem, that can be retained as the "3 X 20" score. A bone 
marrow plasmaeytosis superior to 20%, M-protein levels 
above 20 glL, and a sFLC ratio abm'e 20 at diagnosis can be 
usee! ta risk st!"atify patie:i.ts with SMM u5ing t::'e cur:eŒ: 
IMWG criteria. The estimated median time to progression 
~n the low-risk, intermediace-risk, and high-risk groups were 
109.8 months, 67.8 months and 29.2 months, respecti\'eiy. 
MONITORING OF SMM PATIENTS 
Similar ta MGUS patients, the monitoring of SMM is based 
on clinical (paying attention to signs of a possible MM) and 
biological (blood coums, calcemia, serum creatinine, prorein 
electrophoresis, proteinuriaJ follow-up (Figure 2)." High-risk 
patients need to be [ollowed-up closely (every 3 months) to 
allow the early derection of an evolution towards symptomatic 
MM and [Q avoid devastating complications such as acute 
renai failure, vertebral fractures, spinal cord compression, 
etc. For these patients, sFLC assays and MRIs can be repea-
ced during the follow-up, although there is no standardised 
recommendation on the frequency and intervals of these tests. 
For low-risk SMM patients, the monitoring can be delayed 
(every 6 months) and complementary studies such as sFLC 
and MRI should be repeated in case of signs of progression. 
We believe that prospective studies are needed to define the 
best monitoring strategies for both S[~I~1 patient gTOL:pS . 
EARLY TREATMENT OF HIGH-RISK SMM? 
After the land mark publication of Mateos et al. , other clinical 
trials evaluating early treatment strategies for high-tisk SMM 
have been presentedY These trials eirher aim ar curing 
patients with aggressive ueatments or to control and delay 
progression with a prolonged treatment. Preliminary results 
from 2 studies were presented at ASH 2017. Mateos et al. 
presented the preliminary results of the GEM-CESARstudy, 
a phase Il single-arm trial including 90 patients with a 
high-tisk SMM (defined according to the prognostic scores 
of the Mayo Clinic and/or of the Spanish Myeloma Group)." 
The treatment in this trial eonsisted of earfilzomib, lenalido-
mide and dexamethasone (KRd) as induction, followed By 
HDT-ASCT and consolidation with Krd and Rd maintenance. 
lt has to be acknowledged tbat 30 patients (33%) presemed 
at least one of the new MM diagnostic criteria of 2014. The 
primary endpoint was the aehievement of minimal residual 
disease (MRD) negativity (evaluated by f10w cytometry). At 
the time of the analysis, most patients (N=71) completed the 
6 induction cycles, 42 had received intensification, 35 had 
Patients with SMM 
Exclude presence of 
a myeloma defining avent 
(BM infiltration, MAI and FLC) 
Inclusion in 
Clinlcal trial 
Verity presence of high-rlsk factors 
FIGURE 2. Aigarijhms for patients with smoldering muHiple myelama (SMM). 
received consolidation, and 29 were in the maintenance 
phase. After a median fallow-up of 10 month, 69 patients 
(98%) responded ta treatment after the completion of induc-
tion therapy, about half of wham had a complete response 
(CR) or stringent CR (sCR). Two patients obtained a CR but 
relapsed before the end of induction. MRD negativity and 
depth of response ta treatment increased as patients pro-
gressed through therapy. After the consolidation phase, 
60% of the patients achieved MRD negativity, indicating 
that deep re.sponses can be obtained wÎth an intensive treat-
ment of SMM.'6 Of course, longer follow-up data are needed 
ta assess if this strategy will ultimately cure patients. 
HoJmeister et al. presented the preliminary results of the 
CENTAURUS trial, a randomized phase II study evaluaring 
3 dararumumab dose schedules in 123 SMM patients." There 
were 3 treatment strategies, all including cycles of 8 weeks 
of treatment: (1) a short regimen consisting of 1 cycle of 
daratumumab weekly; (2) an intermediate schedule staring 
with weekly daratumumab in cycle 1 and every 8 weeks up 
ta cycle 20 and (3) a long regimen (weekly daratumumab in 
cycle l , every other week in cycles 2 and 3, every 4 weeks in 
cycles 4 through 7, and every 8 weeks up ta cycle 20). The 
two main endpoints were CR rate and progression-free sur-
vival (PFS). The 12-month PFS rates were 95% with the long 
schedule, 88% with the intermediate dosing schedule, and 
81% with the short, intense schedule. More than haU (54%) 
of the patients in the long arm and 49% in the intermediate 
arrn had a partial response (PR) or better. ln the short arm, 
38% of patients achieved a PR or better. The CR rate was Iess 
than 15% in each arm. These results show that daratumumab 
in monotherapy may induce a haematalogical response and 
delays the progression of high-risk SMM. However, it also 
suggests that the treatment should be extended as shawn 
by the poor results in the short ann. lt is unlikely that dara-
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